ArticleStem cell research & therapy2025
3D TGF-β1-expressing mesenchymal stem cells enhance wound healing in a diabetic mouse model.
Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundHuman mesenchymal stem cells (MSCs) are a promising stem cell source; however, their therapeutic efficacy in chronic wound healing remains limited. This study evaluates the therapeutic potential of transforming growth factor (TGF)-β1-modified, three-dimensionally cultured MSCs (A/T-3D) for enhancing wound healing.
methodsThe TGF-β1 gene was inserted into a safe genomic locus in adipose-derived MSCs (ASCs) using transcription activator-like effector nucleases. Quantitative polymerase chain reaction (qPCR) analysis showed that A/T-3D upregulated key factors related to wound healing, including epidermal growth factor (EGF), TGF-β1, fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF)-A, compared to unmodified ASCs.
resultsIn vitro scratch wound assays indicated that co-culture with A/T-3D-conditioned medium significantly accelerated wound closure in fibroblasts. In vivo, skin excision in nude mice treated with A/T-3D injections resulted in rapid wound closure, enhanced cellularity, and increased reepithelialization. High engraftment rates of A/T-3D and elevated expression of angiogenic factors were observed in the wound bed, highlighting their direct contribution to tissue repair.
conclusionsCollectively, these findings suggest that A/T-3D MSCs have significant therapeutic potential for wound healing through the secretion of epithelialization and angiogenic factors, along with enhanced engraftment capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.